Pfizer surprises Street with Vyndaqel sales, uptake

Uptake of Pfizer's Vyndaqel tafamidis in 3Q19 surpassed a consensus estimate following its approval in May, adding to expectations for a drug the pharma has already touted as a potential blockbuster to treat transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Pfizer Inc. (NYSE:PFE) said Vyndaqel sales jumped to $156 million worldwide

Read the full 471 word article

User Sign In